STAT

FDA broadens search for new top drug regulator after early setbacks

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — The Food and Drug ...

Takeaways from the AP’s report on turmoil surrounding the FDA’s new fast-track drug program

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on drugs cleared under a new plan to slash FDA drug review times.
STAT

FDA review of drugs is slowing while application delays are growing, analysis finds

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
The New York Times

F.D.A. Drug Unit Chief Resigns, and Is Sued by Drug Company

The official, Dr. George Tidmarsh, has become embroiled in an ethical dispute and is now the target of a lawsuit over his actions involving certain drugs tied to a business associate. By Christina ...
Hosted on MSN

Exclusive - US FDA delays two drug reviews in new voucher program after safety, efficacy concerns

Jan 15 (Reuters) - The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and ...